Page last updated: 2024-12-11
octadecenedioic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
octadecenedioic acid: a dermatological and bleaching agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9543674 |
| CHEBI ID | 176959 |
| SCHEMBL ID | 864021 |
| MeSH ID | M0520994 |
Synonyms (25)
| Synonym |
|---|
| 20701-68-2 |
| (z)-octadec-9-enedioic acid |
| octadec-9-ene-1,18-dioic-acid |
| CHEBI:176959 |
| 9z-octadecenedioic acid |
| LMFA01170055 |
| octadecenedioic acid |
| octadecenedioate |
| C19618 |
| 9-octadecenedioic acid, (9z)- |
| unii-565zmt5qrg |
| 565zmt5qrg , |
| octadecenedioic acid [inci] |
| cis-9-octadecenedioic acid |
| o.d.a.white |
| c18:1 dioic acid |
| (z)-9-octadecene-1,18-dioic acid |
| (9z)-9-octadecenedioic acid |
| (z)-9-octadecenedioic acid |
| oristar odda |
| 9-octadecenedioic acid, (z)- |
| SCHEMBL864021 |
| AKOS025401275 |
| Q27261377 |
| DTXSID90885146 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Extensive dose-response experiments were performed using compounds that increased apoA-I transcription by minimally 20%." | ( Large-Scale Screening of Natural Products Transactivating Peroxisome Proliferator-Activated Receptor α Identifies 9S-Hydroxy-10E,12Z,15Z-Octadecatrienoic Acid and Cymarin as Potential Compounds Capable of Increasing Apolipoprotein A-I Transcription in Hum Bendik, I; Böhlendorf, B; Konings, MCJM; Mensink, RP; Plat, J; Popeijus, HE; Tayyeb, J; van der Krieken, SE, 2018) | 0.48 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| long-chain fatty acid | A fatty acid with a chain length ranging from C13 to C22. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 30.30
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.30) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (12.50%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (12.50%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||